Literature DB >> 19549919

Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4.

Yan Xie1, Dennis W Wolff, Taotao Wei, Bo Wang, Caishu Deng, Joseph K Kirui, Haihong Jiang, Jianbing Qin, Peter W Abel, Yaping Tu.   

Abstract

Aberrant signaling through G-protein coupled receptors promotes metastasis, the major cause of breast cancer death. We identified regulator of G-protein signaling 4 (RGS4) as a novel suppressor of breast cancer migration and invasion, important steps of metastatic cascades. By blocking signals initiated through G(i)-coupled receptors, such as protease-activated receptor 1 and CXC chemokine receptor 4, RGS4 disrupted Rac1-dependent lamellipodia formation, a key step involved in cancer migration and invasion. RGS4 has GTPase-activating protein (GAP) activity, which inhibits G-protein coupled receptor signaling by deactivating G-proteins. An RGS4 GAP-deficient mutant failed to inhibit migration and invasion of breast cancer cells in both in vitro assays and a mouse xenograft model. Interestingly, both established breast cancer cell lines and human breast cancer specimens showed that the highest levels of RGS4 protein were expressed in normal breast epithelia and that RGS4 down-regulation by proteasome degradation is an index of breast cancer invasiveness. Proteasome blockade increased endogenous RGS4 protein to levels that markedly inhibit breast cancer cell migration and invasion, which was reversed by an RGS4-targeted short hairpin RNA. Our findings point to the existence of a mechanism for posttranslational regulation of RGS4 function, which may have important implications for the acquisition of a metastatic phenotype by breast cancer cells. Preventing degradation of RGS4 protein should attenuate aberrant signal inputs from multiple G(i)-coupled receptors, thereby retarding the spread of breast cancer cells and making them targets for surgery, radiation, and immune treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549919      PMCID: PMC2741027          DOI: 10.1158/0008-5472.CAN-08-3564

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice.

Authors:  Dandan Shan; Lin Chen; Jon T Njardarson; Christoph Gaul; Xiaojing Ma; Samuel J Danishefsky; Xin-Yun Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

2.  Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.

Authors:  Li Chen; Kiran Madura
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  RGS4 and RGS5 are in vivo substrates of the N-end rule pathway.

Authors:  Min Jae Lee; Takafumi Tasaki; Kayoko Moroi; Jee Young An; Sadao Kimura; Ilia V Davydov; Yong Tae Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-10       Impact factor: 11.205

Review 4.  The great escape: when cancer cells hijack the genes for chemotaxis and motility.

Authors:  John Condeelis; Robert H Singer; Jeffrey E Segall
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

5.  The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Julien Guglielmi; Jean-Claude Bordet; Philippe Clézardin; Olivier Peyruchaud
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

6.  The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis.

Authors:  Patrick Kelly; Benjamin J Moeller; Juhi Juneja; Michelle A Booden; Channing J Der; Yehia Daaka; Mark W Dewhirst; Timothy A Fields; Patrick J Casey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-16       Impact factor: 11.205

7.  Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

Authors:  C H Yang; A M Gonzalez-Angulo; J M Reuben; D J Booser; L Pusztai; S Krishnamurthy; D Esseltine; J Stec; K R Broglio; R Islam; G N Hortobagyi; M Cristofanilli
Journal:  Ann Oncol       Date:  2006-01-10       Impact factor: 32.976

8.  Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells.

Authors:  Jane D Holland; Marina Kochetkova; Chareeporn Akekawatchai; Mara Dottore; Angel Lopez; Shaun R McColl
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

9.  ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.

Authors:  Ming Tan; Ping Li; Kristine S Klos; Jing Lu; Keng-Hsueh Lan; Yoichi Nagata; Dexing Fang; Tong Jing; Dihua Yu
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

10.  Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.

Authors:  Paige J Baugher; Lakshmi Krishnamoorthy; Janet E Price; Surangani F Dharmawardhane
Journal:  Breast Cancer Res       Date:  2005-09-30       Impact factor: 6.466

View more
  65 in total

Review 1.  A finer tuning of G-protein signaling through regulated control of RGS proteins.

Authors:  Jacob Kach; Nan Sethakorn; Nickolai O Dulin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-27       Impact factor: 4.733

2.  RGS4 is a negative regulator of insulin release from pancreatic beta-cells in vitro and in vivo.

Authors:  Inigo Ruiz de Azua; Marco Scarselli; Erica Rosemond; Dinesh Gautam; William Jou; Oksana Gavrilova; Philip J Ebert; Pat Levitt; Jürgen Wess
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

3.  Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.

Authors:  Haihong Jiang; Peter W Abel; Myron L Toews; Caishu Deng; Thomas B Casale; Yan Xie; Yaping Tu
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

4.  Immune/Inflammatory Response and Hypocontractility of Rabbit Colonic Smooth Muscle After TNBS-Induced Colitis.

Authors:  Yonggang Zhang; Fang Li; Hong Wang; Chaoran Yin; JieAn Huang; Sunila Mahavadi; Karnam S Murthy; Wenhui Hu
Journal:  Dig Dis Sci       Date:  2016-02-15       Impact factor: 3.199

5.  DHHC protein-dependent palmitoylation protects regulator of G-protein signaling 4 from proteasome degradation.

Authors:  Jincheng Wang; Yan Xie; Dennis W Wolff; Peter W Abel; Yaping Tu
Journal:  FEBS Lett       Date:  2010-10-28       Impact factor: 4.124

Review 6.  The N-end rule pathway and regulation by proteolysis.

Authors:  Alexander Varshavsky
Journal:  Protein Sci       Date:  2011-08       Impact factor: 6.725

7.  NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth.

Authors:  Irina M Jaba; Zhen W Zhuang; Na Li; Yifeng Jiang; Kathleen A Martin; Albert J Sinusas; Xenophon Papademetris; Michael Simons; William C Sessa; Lawrence H Young; Daniela Tirziu
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

8.  Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.

Authors:  Jin-Chul Heo; Tae-Hoon Jung; Sungjin Lee; Hyun Young Kim; Gildon Choi; Myungeun Jung; Daeyoung Jung; Heung Kyoung Lee; Jung-Ok Lee; Ji-Hwan Park; Daehee Hwang; Ho Jun Seol; Heeyeong Cho
Journal:  Clin Exp Metastasis       Date:  2016-03-08       Impact factor: 5.150

9.  Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling.

Authors:  Paul T Fullerton; Chad J Creighton; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2015-08-18

10.  Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer.

Authors:  Eugene K Lee; Yuanquing Ye; Ashish M Kamat; Xifeng Wu
Journal:  Cancer       Date:  2013-03-25       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.